Arbutus and vaccitech dose first patient in phase 2a clinical trial combining therapies for the treatment of chronic hepatitis b virus

Trial will evaluate ab-729, an rnai therapy in combination with vtp-300, an immunotherapeutic, and na therapy

ABUS Ratings Summary

ABUS Quant Ranking